← Back to Screener
CalciMedica, Inc. Common Stock (CALC)
Price$0.63
Favorite Metrics
Price vs S&P 500 (26W)-89.69%
Price vs S&P 500 (4W)-5.10%
Market Capitalization$9.49M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)0.53x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.37
Price vs S&P 500 (YTD)-94.99%
EPS (TTM)$-1.95
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-1.95
EPS (Annual)$-1.97
ROI (Annual)-95.07%
Cash / Share (Quarterly)$0.84
ROA (Last FY)-217.51%
EBITD / Share (TTM)$-1.51
ROE (5Y Avg)-139.87%
Cash Flow / Share (Annual)$-1.37
P/B Ratio1.56x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-3.41x
ROA (TTM)-162.14%
EPS Incl Extra (Annual)$-1.97
Current Ratio (Annual)3.58x
Quick Ratio (Quarterly)3.46x
3-Month Avg Trading Volume0.90M
52-Week Price Return-60.84%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.14
52-Week High$7.20
EPS Excl Extra (Annual)$-1.97
CapEx CAGR (5Y)-51.28%
26-Week Price Return-80.95%
Quick Ratio (Annual)3.46x
13-Week Price Return-88.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.58x
Enterprise Value$7.674
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.84
3-Month Return Std Dev193.04%
Net Income / Employee (TTM)$-2
ROE (Last FY)-95.07%
Net Interest Coverage (Annual)-1.17x
EPS Basic Excl Extra (Annual)$-1.97
Total Debt / Equity (Quarterly)1.39x
EPS Incl Extra (TTM)$-1.95
ROI (TTM)-145.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$23.21
Price vs S&P 500 (52W)-95.94%
Year-to-Date Return-90.85%
5-Day Price Return-3.66%
EPS Normalized (Annual)$-1.97
ROA (5Y Avg)-142.04%
Month-to-Date Return11.67%
Cash Flow / Share (TTM)$-10.97
EBITD / Share (Annual)$-1.52
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-139.87%
LT Debt / Equity (Quarterly)1.39x
EPS Basic Excl Extra (TTM)$-1.95
P/TBV (Quarterly)1.57x
P/B Ratio (Annual)3.31x
Book Value / Share (Annual)$1.07
Price vs S&P 500 (13W)-91.84%
Beta0.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-206.51%
52-Week Low$0.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CALCCalciMedica, Inc. Common Stock | — | — | — | — | $0.63 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immune-mediated diseases. Its lead candidate, Auxora, is a CRAC channel inhibitor designed to reduce inflammation and cellular damage in organs including the pancreas, lungs, and kidneys. Preclinical studies suggest potential therapeutic benefit for conditions driven by inflammatory and immune dysfunction.